BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 ...
Tiziana Life Sciences Ltd. has announced plans to advance its second asset, a fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501.
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies.
Equivalence of Ina, an AI-based nutrition platform, to human dietitians for counseling patients with cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Often, clinicians and scientists know the mechanism of how a drug or intervention works by the time it makes it into patients in the form of a clinical trial. Yet sometimes, an intervention is shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback